SCHEMBL3362601

SCHEMBL3362601

O=P(O)(O)c1ccc(CO)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.50
CA4 P22748 2/20 0.50
CA5A P35218 2/20 0.50
TSHR P16473 2/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA6 P23280 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
PRSS1 P07477 1/20 0.38
PRSS2 P07478 1/20 0.38
PRSS3 P35030 1/20 0.38
VHL P40337 1/20 0.37
ELOC Q15369 1/20 0.37
ELOB Q15370 1/20 0.37
LTA4H P09960 1/20 0.37
GAA P10253 1/20 0.37
PGK1 P00558 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5667423 0.82 CA2 (0.52) CA2CA4CA5ATSHRPGK1
SCHEMBL8385998 0.81 CA2 (0.50) CA2CA4CA5ATSHRCA12
SCHEMBL2171752 0.81 CA2 (0.71) CA2CA4CA5ATSHRGAA
Diamidophosphate SCHEMBL10932540 0.79 CA1 (0.50) CA2CA4CA5ATSHRCA12
SCHEMBL2597582 0.78 CA2 (0.48) CA2CA4CA5ATSHRPGK1
SCHEMBL344618 0.78 SMN1; SMN2 (0.52) CA2CA4CA5ATSHRLMNA
SCHEMBL13538144 0.78 CA2 (0.48) CA2CA4CA5ACA12CA1
SCHEMBL2208306 0.78 TSHR (0.40) CA2CA4CA5ATSHRCA12
Hydrochloric Acid SCHEMBL22165294 0.76 CA2 (0.46) CA2CA4CA5ACA12CA1
SCHEMBL3399311 0.76 SMN1; SMN2 (0.50) CA2CA4CA5ATSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107987235-A A kind of preparation method of low hydration heat crack resistance type polycarboxylate water-reducer 科之杰新材料集团有限公司 2018-05-04 CN claimed
CN-107987228-A A kind of preparation method of low hydration heat Early-strength polycarboxylate superplasticizer 科之杰新材料集团有限公司 2018-05-04 CN claimed
CN-107987227-A A kind of preparation method of low hydration heat extra retarded set type polycarboxylate water-reducer 科之杰新材料集团有限公司 2018-05-04 CN claimed
CN-107868187-A A kind of preparation method of low hydration heat polycarboxylate water-reducer 科之杰新材料集团有限公司 2018-04-03 CN claimed
US-20230352250-A1 PHOTOELECTRIC CONVERSION ELEMENT, PHOTOELECTRIC CONVERSION MODULE, ELECTRONIC DEVICE, AND POWER SUPPLY MODULE RICOH COMPANY, LTD. (JP) 2023-11-02 US disclosed
CN-107987228-A A kind of preparation method of low hydration heat Early-strength polycarboxylate superplasticizer 科之杰新材料集团有限公司 2018-05-04 CN disclosed
CN-107987235-A A kind of preparation method of low hydration heat crack resistance type polycarboxylate water-reducer 科之杰新材料集团有限公司 2018-05-04 CN disclosed
CN-107987227-A A kind of preparation method of low hydration heat extra retarded set type polycarboxylate water-reducer 科之杰新材料集团有限公司 2018-05-04 CN disclosed
CN-107868187-A A kind of preparation method of low hydration heat polycarboxylate water-reducer 科之杰新材料集团有限公司 2018-04-03 CN disclosed
US-7649015-B2 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds GILEAD SCIENCES, INC. (US) 2010-01-19 US disclosed
CN-101591281-A Phosphonate compounds having immunomodulatory activity GILEAD SCIENCES INC (US) 2009-12-02 CN disclosed
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds GILEAD SCIENCES, INC. 2007-01-11 US disclosed
US-20050239054-A1 Method and compositions for identifying anti-HIV therapeutic compounds GILEAD SCIENCES. INC. 2005-10-27 US disclosed
US-20050209197-A1 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds GILEAD SCIENCES, INC. 2005-09-22 US disclosed
WO-2005064008-A1 METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2005-07-14 WO disclosed
EP-1509537-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2005-03-02 EP disclosed
WO-2003090690-A2 CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH GILEAD SCIENCES, INC. (US) 2003-11-06 WO disclosed
EP-0509769-B1 Heterocyclic amides having HLE inhibiting activity ZENECA LTD (GB) 1996-09-11 EP disclosed
US-5521179-A Heterocyclic amides ZENECA LIMITED (GB) 1996-05-28 US disclosed
EP-0509769-A2 Heterocyclic amides having HLE inhibiting activity ZENECA LIMITED (GB) 1992-10-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209197-A1 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds PPA1, PPME1, PNP CA2 3935/4885CA4 3269/4885CA5A 3294/4885
US-20050239054-A1 Method and compositions for identifying anti-HIV therapeutic compounds CES1, PNP, PGLS CA2 3487/4885CA4 1030/4885CA5A 2188/4885
US-20070010489-A1 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds PPA1, PNP, PPME1 CA2 3915/4885CA4 3211/4885CA5A 2829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.